65. Maguire HC Jr, Hellman ME, Greene MI, Yeh I. 1992. Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast. Pathobiology 60(3):117-121.

66. McCann J, Stockton D, Godward S. 2002. Impact of false-positive mammography on subsequent screening attendance and risk of cancer. Breast Cancer Res 4(5):R11.

67. Meystre-Agustoni G, Paccaud F, Jeannin A, Dubois-Arber F. 2001. Anxiety in a cohort of Swiss women participating in a mammographic screening programme. J Med Screen 8(4):213-219.

68. Mirza NQ, Vlastos G, Meric F, Sahin AA, Singletary SE, Newman LA, Kuerer HM, Ames FC, Ross MI, Feig BW, Pollock RE, Buchholz TA, McNeese MD, Strom EA, Hortobagyi GN, Hunt KK. 2000. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol 7(9):656-664.

69. Mokbel K. 2003. Towards optimal management of ductal carcinoma in situ of the breast. Eur J Surg Oncol 29(2):191-197.

70. Moore E, Magee H, Coyne J, Gorey T, Dervan PA. 1999. Widespread chromosomal abnormalities in high-grade ductal carcinoma in situ of the breast. Comparative genomic hybridization study of pure high-grade DCIS. J Pathol 187(4):403-409.

71. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Harris JR, O’Malley F, Schnitt SJ, Singletary SE, Winchester DP. 2002. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin 52(5):256-276.

72. Mushlin AI, Kouides RW, Shapiro DE. 1998. Estimating the accuracy of screening mammography: a meta-analysis. Am J Prev Med 14(2):143-153.

73. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. 2002. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359(9310):909-919.

74. Olsen O, Gotzsche PC. 2001. Cochrane review on screening for breast cancer with mammography. Lancet 358(9290):1340-1342.

75. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. 1995. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76(7):1197-1200.

76. Page DL, Dupont WD, Rogers LW, Landenberger M. 1982. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 49(4):751-758.

77. Page DL, Gray R, Allred DC, Dressler LG, Hatfield AK, Martino S, Robert NJ, Wood WC. 2001. Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol 24(1):10-18.

78. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR. 1998. Involvement of Brca2 in DNA repair. Mol Cell 1(3):347-357.

79. Pawluczyk O, Augustine BJ, Yaffe MJ, Rico D, Yang J, Mawdsley GE, Boyd NF. 2003. A volumetric method for estimation of breast density on digitized screen-film mammograms. Med Phys 30(3):352-364.

80. Pinckney RG, Geller BM, Burman M, Littenberg B. 2003. Effect of false-positive mammograms on return for subsequent screening mammography. Am J Med 114(2):120-125.

81. Raza S, Rosen MP, Chorny K, Mehta TS, Hulka CA, Baum JK. 2001. Patient expectations and costs of immediate reporting of screening mammography: talk isn’t cheap. Am J Roentgenol 177(3):579-583.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement